Skip to main content

Advertisement

SpringerLink
Log in

The growth-inhibition effect of tamoxifen in the combination chemotherapeutics on the human cholangiocarcinoma cell line QBC939

  • Published:
Molecular Biology Reports Aims and scope Submit manuscript

Abstract

In the individual application of adriamycin, mitomycin, vindesine and their combined application with tamoxifen for the pre-treatment of the human cholangiocarcinoma cell line QBC939, QBC939 was determined by MTT assay to investigate the inhibitive effect and its initial mechanism of TAM on cell growth. Growth cycle and apoptosis of each group were determined by flow cytometry. Concentration of ADM in QBC939 was detected by flow cytometry. The levels of their P-glycoprotein were detected by immunohistochemistry. The mRNA and protein levels of apoptotic-associated genes Bcl-2 and Bax were determined by western blot and real-time PCR. The inhibitive rates of adriamycin, mitomycin, vindesine to QBC939 and the apoptosis rates of QBC939 were enhanced after the pre-treatment of tamoxifen. Influence of tamoxifen in their growth cycle was not so obvious except vindesine group because of the increasing cell numbers of G 2/M phase in which cells may be blocked. The contents of adriamycin in cells rose after the pre-treatment of tamoxifen. Expression level of the multi-drug resistant protein on cell surface was shown as (+). Furthermore, real-time PCR and Western blot analysis revealed an upregulation of Bcl-2 and a downregulation of Bax in QBC939 after the pre-treatment of tamoxifen. Therefore, tamoxifen may have the ability to enhance the relative sensitivity of QBC939 to chemotherapeutics.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7

Similar content being viewed by others

References

  1. Groen PC, Gores GJ, LaRusso NF, Gunderson LL, Nagorney DM (1999) Biliary tract cancers. N Engl J Med 18:1368–1378

    Article  Google Scholar 

  2. Lazaridis KN, Gores GJ (2005) Cholangiocarcinoma. Gastroenterology 128:1655–1667

    Article  PubMed  Google Scholar 

  3. Hur H, Park IY, Sung GY et al (2009) Intrahepatic cholangiocarcinoma associated with intrahepatic duct stones. Asian J Surg 1:7–12

    Google Scholar 

  4. Jarnagin WR, Fong Y, DeMatteo RP et al (2001) Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma. Ann Surg 234(4):507–517 (discussion 517–519)

    Article  CAS  PubMed  Google Scholar 

  5. Todoroki T, Kawamoto T, Koike N et al (2001) Treatment strategy for patients with middle and lower third bile duct cancer. Br J Surg 88(3):364–370

    Article  CAS  PubMed  Google Scholar 

  6. Sagawa N, Kondo S, Morikawa T et al (2005) Effectiveness of radiation therapy after surgery for hilar cholangiocarcinoma. Surg Today 35(7):548–552

    Article  PubMed  Google Scholar 

  7. Pitt HA, Nakeeb A, Abrams RA et al (1995) Perihilar cholangiocarcinoma postoperative radiotherapy does not improve survival. Ann Surg 221(6):788–797 (discussion 797–798)

    Article  CAS  PubMed  Google Scholar 

  8. Shinchi H, Takao S, Nishida H et al (2000) Length and quality of survival following external beam radiotherapy combined with expandable metallic stent for unresectable hilar cholangiocarcinoma. J Surg Oncol 75(2):89–94

    Article  CAS  PubMed  Google Scholar 

  9. Bowling TE, Galbraith SM, Hatfield AR et al (1996) A retrospective comparison of endoscopic stenting alone with stenting and radiotherapy in non-resectable cholangiocarcinoma. Gut 39(6):852–855

    Article  CAS  PubMed  Google Scholar 

  10. Sirica AE (2005) Cholangiocarcinoma: molecular targeting strategies for chemoprevention and therapy. Hepatology 41:5–15

    Article  PubMed  Google Scholar 

  11. Kaassis M, Boyer J, Dumas R et al (2003) Plastic or metal stents for malignant stricture of the common bile duct? Results of a randomized prospective study. Gastrointest Endosc 57(2):178–182

    Article  PubMed  Google Scholar 

  12. Chang WH, Kortan P, Haber GB (1998) Outcome in patients with bifurcation tumors who undergo unilateral versus bilateral hepatic duct drainage. Gastrointest Endosc 47(5):354–362

    Article  CAS  PubMed  Google Scholar 

  13. Prat F, Chapat O, Ducot B et al (1998) Predictive factors for survival of patients with inoperable malignant distal biliary strictures: a practical management guideline. Gut 42(1):76–80

    Article  CAS  PubMed  Google Scholar 

  14. Figueras J, Llado L, Valls C et al (2000) Changing strategies in diagnosis and management of hilar cholangiocarcinoma. Liver Transp l6(6):786–794

    Google Scholar 

  15. Takada T, Amano H, Yasuda H et al (2002) Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma. Cancer 95(8):1685–1695

    Article  PubMed  Google Scholar 

  16. Todoroki T (2000) Chemotherapy for bile duct carcinoma in the light of adjuvant chemotherapy to surgery. Hepatogastroenterology 47(33):644–649

    CAS  PubMed  Google Scholar 

  17. Rao S, Cunningham D, Hawkins RE et al (2005) Phase III study of 5FU, etoposide and leucovorin (FELV) compared to epirubicin, cisplatin and 5FU (ECF) in previously untreated patients with advanced biliary cancer. Br J Cancer 92(9):1650–1654

    Article  CAS  PubMed  Google Scholar 

  18. Glimelius B, Hoffman K, Sjödén PO et al (1996) Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann Onco l7(6):593–600

    Google Scholar 

  19. Shaib Y, El-Serag HB (2004) The epidemiology of cholangiocarcinoma. Semin Liver Dis 24:115–125

    Article  PubMed  Google Scholar 

  20. Han P, Kang JH, Li HL et al (2009) Antiproliferation and apoptosis induced by tamoxifen in human bile duct carcinoma QBC939 cells via upregulated p53 expression. Biochem Biophys Res Commun 385(2):251–256

    Google Scholar 

  21. Tobias JS (2004) Endocrine approaches for the treatment of early and advanced breast cancer in postmenopausal women. Int J Biochem, Cell Biol 36:2112–2119

    Google Scholar 

  22. Grainger J, Metcalfe JC (1996) Tamoxifen: teaching an old drug new tricks? Nat Med 2:381–385

    Article  CAS  PubMed  Google Scholar 

  23. Mandlekar S, Kong AN (2001) Mechanisms of tamoxifen-induced apoptosis. Apoptosis 6:469–477

    Article  CAS  PubMed  Google Scholar 

  24. Carmichael J, DeGraff WG, Gazdar AF et al (1987) Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res 47:936–942

    CAS  PubMed  Google Scholar 

  25. Kerb R, Hoffmeyer S, Brinkmann U (2001) ABC drug tansporters: hereditary polymorphisms and pharmacological impact in MDR1, MRP1 and MRP2. Pharmacogenomics 1:51–64

    Article  Google Scholar 

  26. Hooiveld GJ, Van Montfoort JE, Meijer DK et al (2001) Function and regulation of ATP-binding cassette transport proteins involved in hepatobiliary transport [J]. Eur J Pharm Sci 4:525–534

    Article  Google Scholar 

  27. Ferguson PJ, Brisson AR, Koropatnick J et al (2009) Enhancement of cytotoxicity of natural product drugs against multidrug resistant variant cell lines of human head and neck squamous cell carcinoma and breast carcinoma by tesmilifene. Cancer Lett 2:279–289

    Article  CAS  Google Scholar 

  28. Andersen J, Kamby C, Ejlertsen B et al (2008) Tamoxifen for one year versus two years versus 6 months of Tamoxifen and 6 months of megestrol acetate: a randomized comparison in postmenopausal patients with high-risk breast cancer (DBCG 89C). Acta Onco l4:718–724

    Article  CAS  Google Scholar 

  29. Singh MN, Martin-Hirsch PL, Martin FL (2008) The multiple applications of tamoxifen: an example pointing to SERM modulation being the aspirin of the 21st century. Med Sci Monit 9:RA144–RA148

    Google Scholar 

  30. Incles CM, Schultes CM, Kelland LR et al (2003) Acquired cellular resistance to flavop iridol in a human colon carcinoma cell line involves up-regulation of the telomerase catalytic subunit and telomere elongation. Sensitivity of resistant cells to combination treatment with a telomerase inhibitor 1 [J]. Mol Pharmacol 5:1101–1108

    Article  Google Scholar 

  31. Andrew DG, Giles R (2005) Mathematical modeling of magnetically targeted drug delivery. J Magn Magn Mater 5:455–463

    Google Scholar 

  32. Yoshino T, Hirabe H, Takahashi M et al (2008) Magnetic cell separation using nano-sized bacterial magnetic particles with reconstructed magnetosome membrane. Biotechnol Bioeng 101(3):470–477

    Article  CAS  PubMed  Google Scholar 

  33. Iain B, Kawan S, Sarahl M (2004) Reduced expression of p27 is a novel mechanism of docetaxel resistance in breast cancer cells [J]. Breast Cancer Res 56:601–607

    Google Scholar 

  34. Ghayad SE, Bieche I, Vendrell JA et al (2008) mTOR inhibition reverses acquired endocrine therapy resistance of breast cancer cells at the cell proliferation and gene-expression levels. Cancer Sci 10:1992–2003

    Google Scholar 

Download references

Acknowledgments

The authors thank Shanghai Jiao Tong University Affiliated Sixth People’s Hospital for technical assistance during this study. This work was financially supported by National Natural Science Foundation of China (No. 30672044), and the National Basic Research Program of China (No. 2008CB517403).

Author information

Authors and Affiliations

  1. Department of Surgery, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, 600 Yishan Road, 200233, Shanghai, China

    Zhi-Hua Liu & Huanlong Qin

  2. Department of Surgery, Shanxi Medical University, 030001, Taiyuan, Shanxi, China

    Yan-Ping He

Authors
  1. Zhi-Hua Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yan-Ping He
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Huanlong Qin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Huanlong Qin.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Liu, ZH., He, YP. & Qin, H. The growth-inhibition effect of tamoxifen in the combination chemotherapeutics on the human cholangiocarcinoma cell line QBC939. Mol Biol Rep 37, 2693–2701 (2010). https://doi.org/10.1007/s11033-009-9801-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11033-009-9801-2

Keywords

Search

Navigation